Semaglutide vs Tirzepatide
How they differ on evidence quality, dosing schedule, half-life and cost.
| Semaglutide | Tirzepatide | |
|---|---|---|
| Evidence grade | AApproved, phase 3 data | AApproved, phase 3 data |
| Studied for | GLP-1 weight-management peptide | Dual-action weight-management peptide |
| Half-life | About 1 week | About 5 days |
| Schedule | Once weekly, subcutaneous | Once weekly, subcutaneous |
| Amount in research | 2.4 mg | 15 mg |
| Vial sizes sold | 5 mg, 10 mg | 10 mg, 15 mg, 30 mg, 60 mg |
| Cost | No verified price yet | $134 per dose |
On evidence quality these two sit level, both graded A. Extensive phase 3 data. Approved as Ozempic and Wegovy. For Tirzepatide: Extensive phase 3 data. Approved as Mounjaro and Zepbound. Nothing in the published record separates them, so a choice between them comes down to what is being studied and how it is dosed, and not to one having better support than the other.
An evidence grade describes how strong the research is, and it is not a safety rating or a recommendation. A higher grade on an approved drug does not make a research-use version of it approved.
Semaglutide
It binds GLP-1 receptors in the pancreas to boost glucose-dependent insulin release and lower glucagon. In the brain it acts on appetite centers to increase fullness and slow gastric emptying, which reduces food intake. A fatty-acid chain lets it bind albumin, extending its half-life to about a week. This mechanism is confirmed by large human trials.
Tirzepatide
Tirzepatide is a single molecule that switches on two incretin receptors, GLP-1 and GIP. Together they blunt appetite, slow gastric emptying and improve how the body handles insulin and blood sugar. That dual action is what set it apart from GLP-1 only drugs in head to head trials.
Semaglutide
- Studied for meaningful body-weight reduction in adults with overweight or obesity
- Studied for improved blood-sugar control and lower HbA1c in type 2 diabetes
- May reduce appetite and food cravings by acting on brain appetite centers
- Studied for cardiovascular risk reduction in people with diabetes and heart disease
Tirzepatide
- Studied for weight loss of roughly 15 to 22 percent in adults with obesity or overweight.
- Improves HbA1c and fasting glucose in type 2 diabetes.
- Studied for reduced progression from prediabetes to type 2 diabetes.
- May improve blood pressure, lipids and obstructive sleep apnea measures.
Semaglutide
- Nausea, vomiting, diarrhea and constipation, especially during dose increases
- Risk of gallstones and, rarely, pancreatitis
- May cause dehydration and, in some, low blood sugar when combined with other agents
- Injection-site reactions and appetite loss that can affect nutrition
Tirzepatide
- Nausea, diarrhea, vomiting and constipation, mostly during dose escalation.
- Risk of hypoglycemia when combined with insulin or sulfonylureas.
- Rare gallbladder problems and reports of pancreatitis.
- Carries a boxed warning for a potential risk of thyroid C-cell tumors.
Which has better evidence, Semaglutide or Tirzepatide?
Neither. Both are graded A on our four-point scale, so the published record does not separate them.
How do the dosing schedules differ?
Semaglutide: Once weekly, subcutaneous. Tirzepatide: Once weekly, subcutaneous.
How do their half-lives compare?
Semaglutide: About 1 week. Tirzepatide: About 5 days. Half-life is what the dosing frequency follows from.
Can Semaglutide and Tirzepatide be studied together?
Some research protocols pair compounds and some do not. There is no combined trial data for this pairing on file here, so treat any stacking claim you read elsewhere as untested.
Semaglutide
GLP-1 weight-management peptideA once-weekly GLP-1 peptide studied for lowering blood sugar and reducing appetite.
AApproved, phase 3 dataTirzepatide
Dual-action weight-management peptideA leading weight-management peptide from the SURMOUNT studies, working on two hunger pathways.
AApproved, phase 3 data